Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands
Emerging Infectious Diseases · 2026-11 · 32 (11)
DOI: 10.3201/eid3211.260690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Emerging Infectious Diseases, 2026-11. Verfasst von Merel R Te Marvelde und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Middle East Respiratory Syndrome Coronavirus, Antibodies, Viral, SARS-CoV-2, Coronavirus Infections. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Cross-reactive SARS-CoV-2-specific antibodies could compromise the specificity of MERS-CoV serology, potentially leading to misclassification of infection history. SARS-CoV-2 exposure induced MERS-CoV antibodies primarily targeting the conserved S2 domain, with occasional neutralizing capacity. Combining MERS-CoV S1 binding with neutralization, however, limited the influence of SARS-CoV-2-induced cross-reactivity on MERS-CoV serology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
Te Marvelde, M. R., Mykytyn, A. Z., Raadsen, M. P., Bouffier, A. H. J., Varela, S. B., de Vries, R. D., GeurtsvanKessel, C. H., & Haagmans, B. L. (2026). Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands. Emerging Infectious Diseases, 32(11). https://doi.org/10.3201/eid3211.260690
Vancouver
Te Marvelde MR, Mykytyn AZ, Raadsen MP, Bouffier AHJ, Varela SB, de Vries RD, et al. Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands. Emerging Infectious Diseases. 2026;32(11). doi:10.3201/eid3211.260690
BibTeX
@article{TeMarvelde2026,
author = {Te Marvelde, Merel R and Mykytyn, Anna Z and Raadsen, Matthijs P and Bouffier, Alexandre H J and Varela, Sivana Baptista and de Vries, Rory D and GeurtsvanKessel, Corine H and Haagmans, Bart L},
title = {Serologic Testing for Middle East Respiratory Syndrome Coronavirus and SARS-CoV-2 Cross-Reactive Immune Responses, the Netherlands},
journal = {Emerging Infectious Diseases},
year = {2026},
volume = {32},
number = {11},
doi = {10.3201/eid3211.260690}
}
EUVIMED